{"schema_version":"secwatch.filing_event.v1","accession":"0001193125-25-033718","form_type":"8-K","ticker":null,"cik":"0001808158","company_name":"Repare Therapeutics Inc.","filed_at":"2025-02-25T23:59:59+00:00","discovered_at":"2026-05-14T18:03:04.962697+00:00","generated_at":"2026-05-26T04:53:03.150482+00:00","sec_items":["2.05","5.02"],"event_type":"other_material","sentiment":"negative","materiality_score":0.85,"calibrated_materiality_score":0.85,"confidence":"high","headline":"Repare Therapeutics cuts workforce ~75%, expects $21M annual savings; CMO departs","bullets":["Board approved ~75% workforce reduction on Feb 23, 2025; affected employees notified Feb 24.","One-time cash charges: ~$7.3M severance + up to $1.4M retention costs, through Q4 2025.","Annual operating expense savings of ~$21M expected from the reorganization.","CMO Maria Koehler to depart March 31, 2025; severance includes nine months salary, $150k payment, COBRA, equity acceleration.","CFO Steve Forte gets $175k retention bonus; CSO Mike Zinda receives $150k retention bonus."],"urls":{"canonical":"https://secwatch.observer/filing/0001193125-25-033718","json":"https://secwatch.observer/filing/0001193125-25-033718.json","markdown":"https://secwatch.observer/filing/0001193125-25-033718.md","text":"https://secwatch.observer/filing/0001193125-25-033718.txt","edgar_index":"https://www.sec.gov/Archives/edgar/data/1808158/000119312525033718/0001193125-25-033718-index.htm","edgar_primary_document":"https://www.sec.gov/Archives/edgar/data/1808158/000119312525033718/d859090d8k.htm"},"model":{"generated_by":"deepseek-v4-flash:cloud@v2","generated_at":"2026-05-26T04:53:03.150482+00:00"},"review":{"review_status":"machine_generated","human_reviewed":false,"corrected":false,"correction_note":null,"correction_timestamp":null,"superseded_by":null,"related_filings":[]},"source_grounded_claims":[{"claim_id":"ec26a388095f71fcae3c36d99628e8887e496454","claim":"Repare Therapeutics Inc. announced a restructuring with charges of approximately $7.3 million related to employee severance payments and related costs (approximately 75%).","evidence_excerpt":"These plans were communicated to affected employees on February 24, 2025. The Company expects to incur one-time cash charges associated with the Reorganization of approximately $7.3 million related to employee severance payments and related costs, which are expected to be incurred through the fourth quarter of 2025. In addition, the Company has committed to pay","evidence_source":"SEC 8-K Item 2.05/2.06","evidence_url":"https://www.sec.gov/Archives/edgar/data/1808158/000119312525033718/0001193125-25-033718-index.htm","confidence":0.9,"family_label":"Restructurings & Charges","details":[{"label":"Type","value":"restructuring"},{"label":"Charge","value":"approximately $7.3 million related to employee severance payments and related costs"},{"label":"Headcount","value":"approximately 75%"}],"fact_type":"restructuring_charge"}],"license":"Source filings: public domain (SEC EDGAR). Summaries (headline + bullets): CC-BY-4.0; attribute https://secwatch.observer"}